<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4428">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341727</url>
  </required_header>
  <id_info>
    <org_study_id>202003188</org_study_id>
    <nct_id>NCT04341727</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection</brief_title>
  <acronym>WU352</acronym>
  <official_title>WU 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III trial four treatment strategies non-critically ill hospitalized participants&#xD;
      (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection,&#xD;
      Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase III trial will utilize four treatment strategies in non-critically ill&#xD;
      hospitalized participants (not requiring mechanical ventilation) with SARS CoV-2 infection,&#xD;
      Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.&#xD;
      Investigators are primarily interested in the time to recovery. In addition to study&#xD;
      medications there will be daily symptom surveys for 14 days, then weekly thereafter for 4&#xD;
      weeks resulting in a total duration of follow up of 42 days. During hospitalization, daily&#xD;
      symptom surveys will be completed in conjunction withthe study coordinators. On discharge&#xD;
      participants will have the option to complete electronic symptom surveys or complete symptom&#xD;
      surveys via telephone with study coordinator. In the event that the participant opts for&#xD;
      electronic symptom surveys on discharge participants will in addition receive a follow up&#xD;
      call from a study coordination every 7 days during the initial 14 day period. In addition,&#xD;
      failure to submit a symptom survey will prompt a study follow up call. Data from SOC will be&#xD;
      collected from medical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    DSMB recommended study suspension slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 4, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hours to recovery</measure>
    <time_frame>42 days</time_frame>
    <description>Time (hours) from randomization to recovery defined as 1) absence of fever, as defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications AND 2) absence of symptoms of greater than mild severity for 24 hours AND 3) not requiring supplemental oxygen beyond pre-COVID baseline AND 4) freedom from mechanical ventilation or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time fever resolution</measure>
    <time_frame>42 days</time_frame>
    <description>Time to resolution of fever defined as at least 48 hours since last temperature ≥ 38.0°C without the use of fever-reducing medications</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine plus azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2: Hydroxychloroquine 400mg orally twice a day for one day, followed by 200mg twice a day for four consecutive days (Five days in total). The drug will be supplied in 200mg tablets.&#xD;
AND Azithromycin 500mg orally once, followed by 250mg daily for four consecutive days (five days total). The drug will be supplied in 250mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 3: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine plus azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 4: Chloroquine phosphate 1000mg orally once, followed in 12 hours by 500mg, then 500mg orally twice daily for 4 days (Five days in total). The drug will be supplied in 500mg tablets.&#xD;
AND Azithromycin 500mg orally once, followed by 250mg daily for 4 consecutive days (5 days total).The drug will be supplied in 250mg tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate</intervention_name>
    <description>anti-rheumatic drug (DMARD)</description>
    <arm_group_label>Hydroxychloroquine alone</arm_group_label>
    <arm_group_label>Hydroxychloroquine plus azithromycin</arm_group_label>
    <other_name>HYDROXYCHLOROQUINE Plaquenil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Chloroquine plus azithromycin</arm_group_label>
    <arm_group_label>Hydroxychloroquine plus azithromycin</arm_group_label>
    <other_name>COMMON BRAND(S): Zithromax GENERIC NAME(S): Azithromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine Sulfate</intervention_name>
    <description>Antimalarial</description>
    <arm_group_label>Chloroquine alone</arm_group_label>
    <arm_group_label>Chloroquine plus azithromycin</arm_group_label>
    <other_name>Aralen GENERIC NAME(S): Chloroquine Phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalization for management of SARS CoV-2 infection&#xD;
&#xD;
          -  Positive SARS CoV-2 test&#xD;
&#xD;
          -  Age &gt;=18 years&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
          -  Electrocardiogram (ECG) ≤48 hours prior to enrollment&#xD;
&#xD;
          -  Complete blood count, glucose-6 phosphate-dehydrogenase (G6PD), comprehensive&#xD;
             metabolic panel and magnesium ≤48 hours prior to enrollment from standard of care.&#xD;
&#xD;
          -  If participating in sexual activity that could lead to pregnancy, individuals of&#xD;
             reproductive potential who can become pregnant must agree to use contraception&#xD;
             throughout the study. At least one of the following must be used throughout the study:&#xD;
&#xD;
               -  Condom (male or female) with or without spermicide&#xD;
&#xD;
               -  Diaphragm or cervical cap with spermicide&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Hormone-based contraceptive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication or allergy to chloroquine, hydroxychloroquine or azithromycin&#xD;
&#xD;
          -  Current use hydroxychloroquine, chloroquine or azithromycin&#xD;
&#xD;
          -  Concurrent use of another investigational agent&#xD;
&#xD;
          -  Invasive mechanical ventilation&#xD;
&#xD;
          -  Participants who have any severe and/or uncontrolled medical conditions such as:&#xD;
&#xD;
               -  unstable angina pectoris,&#xD;
&#xD;
               -  symptomatic congestive heart failure,&#xD;
&#xD;
               -  myocardial infarction,&#xD;
&#xD;
               -  cardiac arrhythmias or know prolonged QTc &gt;470 males, &gt;480 female on ECG&#xD;
&#xD;
               -  pulmonary insufficiency,&#xD;
&#xD;
               -  epilepsy (interaction with chloroquine),&#xD;
&#xD;
          -  Prior retinal eye disease&#xD;
&#xD;
          -  Concurrent malignancy requiring chemotherapy&#xD;
&#xD;
          -  Known Chronic Kidney disease, eGFR&lt;10 or dialysis&#xD;
&#xD;
          -  G-6-PD deficiency, if unknown requires G6PD testing prior to enrollment&#xD;
&#xD;
               -  Known Porphyria&#xD;
&#xD;
               -  Known myasthenia gravis&#xD;
&#xD;
               -  Currently pregnant or planning on getting pregnant while on study&#xD;
&#xD;
               -  Breast feeding&#xD;
&#xD;
               -  AST/ALT &gt;five times the upper limit of normal ULN*&#xD;
&#xD;
               -  Bilirubin &gt;five times the ULN*&#xD;
&#xD;
               -  Magnesium &lt;1.4 mEq/L*&#xD;
&#xD;
               -  Calcium &lt;8.4mg/dL &gt;10.6mg/dL*&#xD;
&#xD;
               -  Potassium &lt;3.3 &gt;5.5 mEg/L*&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane O'Halloran, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine (ID-CRU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine Infectious Disease Clinical Research Unit</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jane O'Halloran</investigator_full_name>
    <investigator_title>Assistant Professor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

